Department of Neurology, Medical College of Georgia, 1122 15th Street, Augusta, GA 30912, USA.
Stroke. 2011 Sep;42(9):2633-5. doi: 10.1161/STROKEAHA.111.618215. Epub 2011 Jul 7.
Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.
The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.
Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).
Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.
血浆基质金属蛋白酶-9 水平可预测组织型纤溶酶原激活物（tPA）后出血。
作者研究了米诺环素对 MINOS 试验和对照组急性缺血性脑卒中患者血浆基质金属蛋白酶-9 的影响。
MINOS 组（tPA，P=0.0022；非 tPA，P=0.0066）与基线相比，72 小时时基质金属蛋白酶-9 水平较基线下降，且在 24 小时时低于非 MINOS 对照组（tPA，P<0.0001；非 tPA，P=0.0019）。
MINOS 试验中接受 tPA 治疗的患者血浆基质金属蛋白酶-9 水平较低。米诺环素与 tPA 联合使用可能通过抑制基质金属蛋白酶-9 活性来预防溶栓治疗的不良后果。
